China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024
The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price...
Policy / Regulatory
China’s NMPA Issues Guidelines for Inspection of Third-Party Online Drug Trading Platforms
The National Medical Products Administration (NMPA) has issued a new set of “Guidelines for the...
Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate
The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...
China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training
The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...
China’s CDE Releases Guidelines for CGT Clinical Trials Communication
The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...
China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste
The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...
China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities
The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...
China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...
China Charts Course for Advanced Disease Prevention and Control System by 2030
China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...
China’s NHC Releases Third List of Recommended Generic Drugs for Development
The National Health Commission (NHC) of China has released its third list of drugs recommended...
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...
CNIPA Releases Updated Patent Law Rules with Pharma Industry in Focus
The China National Intellectual Property Administration (CNIPA) has announced the “Decisions of the State Council...
China’s CDE Issues Draft Guidelines for Overseas Drug Market Approval Filings
China’s Center for Drug Evaluation (CDE) has unveiled a draft set of “Application Material Requirements”...
China Announces New Hospital Inspection Measures to Standardize Healthcare System
The National Health Commission (NHC), in collaboration with the National Administration of Traditional Chinese Medicine...
China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies
The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...
Jiangsu Initiates Sunshine Procurement Round for Medical Consumables with 46 Products
The Jiangsu Public Resource Trading Platform has announced a new round of sunshine online procurement...
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL)...
Hong Kong Aims for “First-Level Approvals” with New Drug Regulatory Institution
Hong Kong is taking steps to establish a drug regulatory institution that will permit “first-level...
CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20
The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...